[HTML][HTML] Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast …
M Lambertini, HCF Moore, RCF Leonard… - Journal of clinical …, 2018 - ncbi.nlm.nih.gov
Purpose The role of temporary ovarian suppression with gonadotropin-releasing hormone
agonists (GnRHa) during chemotherapy as a strategy to preserve ovarian function and …
agonists (GnRHa) during chemotherapy as a strategy to preserve ovarian function and …
[HTML][HTML] Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet™)
RCF Leonard, S Williams, A Tulpule, AM Levine… - The Breast, 2009 - Elsevier
Anthracyclines are valuable cytotoxic agents in cancer treatment. However, their usefulness
is limited by cumulative dose-dependent cardiotoxicity that may manifest as life-threatening …
is limited by cumulative dose-dependent cardiotoxicity that may manifest as life-threatening …
Continuous 5-fluorouracil in the treatment of breast cancer
DA Cameron, H Gabra, RCF Leonard - British journal of cancer, 1994 - nature.com
Abstract Prolonged infusions of 5-fluorouracil (5-FU) have been used since the early 1960s,
but recently there has been a major resurgence of interest, partly because of the advent of …
but recently there has been a major resurgence of interest, partly because of the advent of …
Characterization and properties of nine human ovarian adenocarcinoma cell lines
…, IP Hayward, DJ Schol, J Hilgers, RCF Leonard… - Cancer research, 1988 - AACR
Four series of cell lines have been derived from patients with ovarian adenocarcinoma. Nine
cell lines have been established at different stages of treatment: eight from malignant …
cell lines have been established at different stages of treatment: eight from malignant …
Chemotherapy prolongs survival in inoperable pancreatic carcinoma
…, A Cull, DC Carter, RCF Leonard - British journal of …, 1994 - Wiley Online Library
Forty‐three patients with irresectable advanced pancreatic cancer were randomized to
receive chemotherapy using a combination of 5‐fluorouracil, Adriamycin and mitomycin or …
receive chemotherapy using a combination of 5‐fluorouracil, Adriamycin and mitomycin or …
[PDF][PDF] Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an …
…, AL Jones, M Highley, RCF Leonard… - Journal of Clinical …, 2005 - academia.edu
Phase III Randomized Trial of Doxorubicin and Docetaxel Versus Doxorubicin and
Cyclophosphamide As Primary Medical Therapy in Wo Page 1 Phase III Randomized Trial of …
Cyclophosphamide As Primary Medical Therapy in Wo Page 1 Phase III Randomized Trial of …
[HTML][HTML] Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer
…, K McAdam, L Foster, RCF Leonard… - … England Journal of …, 2006 - Mass Medical Soc
Background The National Epirubicin Adjuvant Trial (NEAT) and the BR9601 trial examined
the efficacy of anthracyclines in the adjuvant treatment of early breast cancer. Methods In …
the efficacy of anthracyclines in the adjuvant treatment of early breast cancer. Methods In …
Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening
…, BB Muir, JB Scrimgeour, RCF Leonard… - Journal of Clinical …, 1999 - ascopubs.org
PURPOSE: Tamoxifen is the most commonly prescribed adjuvant therapy for women with
breast cancer. It has agonist activity on the endometrium and is associated with an …
breast cancer. It has agonist activity on the endometrium and is associated with an …
[HTML][HTML] GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial
RCF Leonard, DJA Adamson, G Bertelli, J Mansi… - Annals of …, 2017 - Elsevier
Background Chemotherapy-induced premature ovarian insufficiency (POI) impacts fertility
and other aspects of women's health. The OPTION trial tested whether administration of a …
and other aspects of women's health. The OPTION trial tested whether administration of a …
[HTML][HTML] Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer
DA Cameron, C Massie, G Kerr, RCF Leonard - British journal of cancer, 2003 - nature.com
Despite the extensive literature clearly demonstrating the survival benefit for adjuvant
chemotherapy in women with operable breast cancer, there are few data confirming this in …
chemotherapy in women with operable breast cancer, there are few data confirming this in …